A new €2 million programme designed to advance research into neurological conditions has been launched in Ireland.
The research training scheme will bring 11 postdoctoral researchers from around the world to Ireland, and aims to equip them with the skills needed to progress their research into diseases such as MS, MND, Parkinson’s, and neurodevelopmental conditions.
Successful applicants will receive training in cutting-edge technologies including gene therapy, high-resolution imaging, precision medicine, biomolecule and gene delivery and digital health.
They will also access placements in hospital and industry settings, to help their research findings to be translated into diagnostics, treatments or devices that improve the lives of those affected by neurological diseases.
The NeuroAdapt programme has been launched by RCSI University of Medicine and Health Sciences. It was supported by €1m from the European Commission’s Marie Skłodowska-Curie Actions (MSCA) 2023 COFUND and €1m from research centre, FutureNeuro.
Academic lead for the project, Dr Tobias Engel, says: “Brain diseases represent one of the most pressing health challenges today, and while we’ve seen an explosion of new treatments—from novel diagnostic devices to more effective drugs and the integration of AI in healthcare—there’s a growing need for researchers who can turn these innovations into optimal patient care.
“NeuroAdapt is designed to bridge this gap by providing top-tier research training that prepares the next generation of neuroscientists to lead in this rapidly evolving field.
“This initiative will strengthen Ireland’s position at the forefront of neuroscience research while aligning with global health priorities, including the UN Sustainable Development Goals and the EU’s Healthier Together initiative.”
